← Pharming Group NV overview

Pharming Group NV vs Alnylam Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Pharming Group NV (PHARM.AS)

Q3 2026
▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

  • Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.

    The guidance cut is the single biggest negative force behind the stock's move this period.

  • Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.

    It is a new negative overhang that can affect the stock beyond the one-day drop.

  • Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.

    These approvals are the main positive counterweight to the weak RUCONEST story.

  • CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.

    An abrupt CEO departure is a fresh governance risk that can hold the stock back.

August 2026
▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

  • Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.

    The guidance cut is the single biggest negative force behind the stock's move this period.

  • Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.

    It is a new negative overhang that can affect the stock beyond the one-day drop.

  • Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.

    These approvals are the main positive counterweight to the weak RUCONEST story.

  • CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.

    An abrupt CEO departure is a fresh governance risk that can hold the stock back.

Latest
▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

  • Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.

    The guidance cut is the single biggest negative force behind the stock's move this period.

  • Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.

    It is a new negative overhang that can affect the stock beyond the one-day drop.

  • Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.

    These approvals are the main positive counterweight to the weak RUCONEST story.

  • CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.

    An abrupt CEO departure is a fresh governance risk that can hold the stock back.

Alnylam Pharmaceuticals Inc (ALNY)

Q3 2026
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

July 2026
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Latest
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Q2 2026
▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

June 2026
▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.